To provide long-term clinical data supporting the use of lumateperone in maintaining stability and reducing relapse risk in adults with schizophrenia.
Approach:
Key Findings:
Lumateperone significantly prolonged time to relapse compared to placebo (p=0.0002).
Reduced risk of relapse by 63% (hazard ratio, 0.37).
84% of patients receiving lumateperone remained relapse-free at 6 months.
Significantly delayed time to all-cause treatment discontinuation.
Common treatment-related adverse event was headache, occurring in at least 5% of patients.
Interpretation:
Lumateperone demonstrates efficacy in preventing relapse in schizophrenia, with a favorable safety profile and no new safety concerns identified.
Limitations:
The exact mechanism of action of lumateperone is not fully understood.
Long-term effects beyond 12 months are not assessed.
Conclusion:
The label update reinforces lumateperone's role in maintaining disease stability in schizophrenia, alongside its existing approvals for other psychiatric conditions.
